Similar to the assessment of other biomarkers for the pharmacognostic, the analysis of MSI status could be conditioned by the usual disadvantages linked to biopsy samples including the small amount of biomaterial available which could affect the subsequent molecular confirmation and the tumor heterogeneity, especially with MSH6 staining, as previously reported [16]. Here, MSH6 is linked to neoplasm.